Agrupus - Company finances
|
EUR
|
2023
From: 2023-07-31
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 1,167 | 18,920 | 127,381 |
| Profit before tax | -17,549 | -23,397 | -16,233 |
| Net profit | -17,549 | -23,397 | -16,233 |
| Equity | -17,549 | -23,397 | -16,233 |
| Liabilities | 19,368 | 27,308 | 18,028 |
| Non-current assets | 0 | 0 | 0 |
| Current assets | 1,819 | 3,911 | 1,795 |
| Total assets | 1,819 | 3,911 | 1,795 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +1521.3% | +573.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -964.8% | -598.2% | -904.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -1503.8% | -123.7% | -12.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -1503.8% | -123.7% | -12.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Agrupus - Social security debts
The company had no debts to Sodra
Agrupus - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-08-28 | 2025-09-23 | 2.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Agrupus, MB (code 306370123) is a small partnership engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €127.4K and recorded a net loss of €16.2K, which corresponds to a profit margin of -12.7%. This was a notable improvement from 2024, when revenue was €18.9K and the net loss reached €23.4K, and from 2023, when turnover was only €1.2K and the company also posted a loss. The revenue trend over the latest three years shows a sharp expansion in sales, while losses have narrowed in relative terms. At the same time, profitability remains negative and equity was still negative at the end of 2025. Total assets were €1.8K, with liabilities of €18.0K, indicating a highly leveraged and very small balance sheet structure. Asset turnover was unusually high because of the limited asset base, so efficiency ratios should be interpreted cautiously.